Utilizing our de novo approach, we have created a state-of-the-art DL platform for genome annotation and protein discovery. Our platform relies on superior pattern recognition of DL-based algorithms versus conventional sequence alignment-based methods. This represents a major paradigm shift in DNA annotation and protein discovery.
Trained on > 100 million proteins, our state-of-the-art DL protein model can be supplemented with public and customer data for any trait of interest. Utilizing transfer learning we can work with small customer data sets. The DL model learns the trait and we test billions of amino acid permutations for desired function in silico. The outcome? Improved proteins for function, faster than ever before.
When the right fit cannot be discovered or engineered, a radically different approach is required. We are developing generative DL models to design proteins from scratch. Our vision is to generate novel proteins de novo for any desired function in the not-so-distant future. Universal vaccines, personalized therapeutics, healthier and more sustainable crops, cleaner fuel- it is all attainable with de novo design. We see no limit other than our imagination.
Founded by genomics and synthetic biology experts, we have spent decades solving complex biological problems and are passionate about creating life-changing AI solutions that will revolutionize life sciences as we know it.
Integration of Denovium Engine™ with AbSci’s Protein Printing™ Platform to enable creation of novel biotherapeutics and manufacturing cell lines with a click of a button
Read More Primordial Genetics, a synthetic biology company, and Denovium Inc., an artificial intelligence company, are collaborating to develop novel and more efficient enzymes for DNA synthesis to ultimately impact the diagnosis, prevention and treatment of human diseases, such as cancer, heart disease, HIV and genetic diseases, such as cystic fibrosis. The research and development project is supported through a grant by the National Human Genome Research Institute of the National Institutes of Health.
Read More Our CEO, Toby Richardson, will be presenting at SynBioBeta this year alongside Nobel Laureate Frances Arnold and many other leaders in the field!
Read More Denovium and Maxygen announced today the formation of a strategic partnership centered on the application of Denovium’s artificial intelligence (AI) platform to Maxygen’s molecular breeding technology.
Read MoreWe have ongoing relationships with a number of trusted institutions across the life sciences. Let us know how we can help, we are open to exploring new opportunities and collaborations.
We believe that our technology has the potential to radically transform the world into a better place and that is what motivates us to give it our all every day. While we have a strong work ethic, we are also firm believers of the importance of work life balance. Like they say in latin, mens sana in corpore sano- a healthy mind in a healthy body!
With flexible hours, and in some cases, option to work remote, we practice what we preach. If you share our vision and appreciate working at a cutting-edge biotechnology company that also knows how to have fun, send us your CV. We would love to learn a little bit more about you!
We believe that our technology has the potential to radically transform the world into a better place and that is what motivates us to give it our all every day. While we have a strong work ethic, we are also firm believers of the importance of work life balance. Like they say in latin, mens sana in corpore sano- a healthy mind in a healthy body!
With flexible hours, and in some cases, option to work remote, we practice what we preach. If you share our vision and appreciate working at a cutting-edge biotechnology company that also knows how to have fun, send us your CV. We would love to learn a little bit more about you!
Home
Technology
Team
News
Partners
Careers
Contact
